Concord Biotech Limited receives EIR for Unit III

Concord Biotech Limited has announced that the United States Food and Drug Administration (USFDA) had conducted an inspection at Company's Manufacturing Unit III, Plot No. 84 And 668, Ranasar and Malawada, Limbasi Sojitra Road, Near Limbasi, Taluka- Matar, Kheda, Gujarat from Monday, 26th June, 2023 to Friday 30th June, 2023.

Pursuant to the above inspection by United States Food and Drug Administration (USFDA), the Company has now received the Establishment Inspection Report (EIR) indicating closure of inspection and classifying the facility as "no action indicated" ("NAI").

Based on this inspection and the USFDA NAI classification, this facility is in compliance with regard to current good manufacturing practices (cGMP).

Shares of Concord Biotech Limited was last trading in BSE at Rs. 993.45 as compared to the previous close of Rs. 956.35. The total number of shares traded during the day was 326675 in over 17916 trades.

The stock hit an intraday high of Rs. 1022.00 and intraday low of 936.25. The net turnover during the day was Rs. 322241282.00.

Source : Equity Bulls

Keywords

ConcordBiotech Pharmaceuticals INE338H01029 EIR USFDA Unit3